Baseline characteristics | n | % |
---|---|---|
N | 2199 | 100 |
Gender | ||
Female | 1233 | 56 |
Male | 0965 | 43 |
Diverse | 0001 | 01 |
Year of birth | ||
1991–2003 (approx. 18–30 years) | 0419 | 19 |
1971–1990 (approx. 31–50 years) | 0772 | 35 |
1951–1970 (approx. 51–70 years) | 0859 | 39 |
1933–1950 (approx. 70–88 years) | 0149 | 07 |
Residence | ||
Rural areaa | 0618 | 28 |
Small townb | 0642 | 29 |
Medium-sized townc | 0223 | 10 |
Cityd | 0716 | 33 |
Employment | ||
Employed | 1525 | 69 |
In education | 0228 | 10 |
Unemployed | 0050 | 02 |
Retired | 0336 | 15 |
Other | 0040 | 02 |
Not specified | 0020 | 01 |
Education | ||
No degree | 0002 | 01 |
Lower certificate | 0055 | 02 |
Intermediate certificate | 0273 | 12 |
Complete apprenticeship | 0321 | 15 |
High school diploma | 0459 | 21 |
University degree | 1047 | 48 |
Not specified | 0042 | 02 |
Vaccination | ||
Control group | 0024 | 01 |
Covid-19 | 2175 | 99 |
First vaccination COVID (n = 2175) | ||
BNT162b2 (BioNTech/Pfizer) | 1313 | 60 |
mRNA-1273 (Moderna) | 0253 | 12 |
ChadOx1 (AstraZeneca) | 0609 | 28 |
Ad26.COV2.S (Johnson & Johnson) | 0000 | 00 |
Second vaccination COVID (n = 1753) | ||
BNT162b2 (BioNTech/Pfizer) | 1200 | 68 |
mRNA-1273 (Moderna) | 0375 | 21 |
ChadOx1 (AstraZeneca) | 0141 | 08 |
Ad26.COV2.S (Johnson & Johnson) | 0000 | 00 |
Cancelled | 0005 | 01 |
Not planned | 0032 | 02 |
NA | 0422 | |
Health status | ||
No preexisting diseases | 0832 | 38 |
Allergies | 0598 | 27 |
Hypertension | 0408 | 19 |
Back pain | 0331 | 15 |
Lung disease | 0187 | 9 |
Rheumatism/autoimmune disease | 0172 | 8 |
Depression | 0153 | 7 |
Osteoarthritis | 0142 | 6 |
Gastrointestinal disease | 0135 | 6 |
Heart disease | 0117 | 5 |
Diabetes | 0094 | 4 |
Cancer | 0072 | 3 |
Coagulation problems | 0044 | 2 |
Kidney disease | 0040 | 2 |
Liver disease | 0034 | 2 |
Anaemia | 0028 | 1 |
Mean | SD | |
mSCQ-D (n = 2199)e | 0001.6 | 02.4 |
BMI (n = 2176)f | 0026.2 | 05.8 |